Article
Transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-related drug targets for cardiometabolic diseases.
Nature communications - 28 Oct 2024
Wu Xueyan, Ying Hui, Yang Qianqian, Yang Qian, Liu Haoyu, Ding Yilan, Zhao Huiling, Chen Zhihe, Zheng Ruizhi, Lin Hong, Wang Shuangyuan, Li Mian, Wang Tiange, Zhao Zhiyun, Xu Min, Chen Yuhong, Xu Yu, Vincent Emma E, Borges Maria Carolina, Gaunt Tom R, Ning Guang, Wang Weiqing, Bi Yufang, Zheng Jie, Lu Jieli
Abstract excerpt
Immunity has shown potentials in informing drug development for cardiometabolic diseases, such as type 2 diabetes (T2D) and coronary artery disease (CAD). Here, we performed a transcriptome-wide Mendelian randomization (MR) study to estimate the putative causal effects of 11,021 gene expression profiles during CD4+ T cells activation on the development of T2D and CAD. Robust MR and colocalization evidence was...
Topics
Join the communities discussing this publication.
